LifeHealth, LLC has acquired the IRMA TruPoint Blood Analysis System.  LifeHealth plans to continue to build on the foundation of the IRMA TruPoint product line and continue the development of its proprietary new measures that the Company believes will have a significant impact on improving health.

The IRMA TruPoint system was the first device to bring laboratory grade blood gas analyses to the patient bedside and continues to offer an accurate and reliable menu of blood analytes.  With room temperature stored single-use analysis cartridges, the IRMA TruPoint system is an accurate, low maintenance device with international appeal. The system measures a wide variety of the most critical and highest test volume parameters for use in a multitude of distributed patient care settings. The system’s test menu includes blood gases, electrolytes and additional clinical chemistry test panels that are delivered within two minutes with lab quality accuracy.

In addition to the IRMA TruPoint product line, the acquisition gives LifeHealth a fully staffed world-class manufacturing and R & D facility and a foundation of business that will propel LifeHealth forward.  LifeHealth has been developing a proprietary advanced point-of-care panel of analytes that will have major health implications. The acquisition provides the commercial infrastructure to bring this new measure to market efficiently.

Mike Sinsheimer, CEO of LifeHealth, commented, “We are very pleased to acquire such meaningful assets and expertise, which allows us to advance our objective of providing diagnostic technology that helps save lives and improve the quality of care in urgent settings.  We are also pleased that our sales partner, Accriva Diagnostics will continue selling the product line, which should ensure a smoother transition of ownership for all of our customers and international distributors.”  Scott Blomberg, President and COO of LifeHealth, added, “As one of the early members of the pioneering IRMA TruPoint team and the leader of the LifeHealth development efforts, I am pleased to bring these two teams together to form one highly capable organization.  We are excited to leverage the strengths of the IRMA TruPoint product line and the new LifeHealth analytes to provide better diagnostic information to clinicians.”

Scott Cramer, CEO and President of Accriva Diagnostics, stated, “We are happy that this transaction enables our former employees at the IRMA facility in Roseville, Minnesota to be a part of a company that is focused on enhancing the IRMA TruPoint product line, while Accriva can now direct all of our development resources to our core hemostasis management diagnostic products.”

Source: PRnewswire